Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3918-3927

  Zhang, Qing Mei ^a   He, Shu Jia ^a   Shen, Ning ^b   Luo, Bin ^a   Fan, Rong ^a   Fu, Jun ^a   Luo, Guo Rong ^a   Zhou, Su Fang ^a   Xiao, Shao Wen ^c   Xie, Xiao Xun ^a  

^a Department of Histology and Embryology School of Pre clinical Medicine   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; MAGE D4; Melanoma associated antigen; Serum immunoreactivity

Indexed keywords

MAGED1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; COLORECTAL TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84906215670     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
3. Zafar SY, Malin JL, Grambow SC, Abbott DH, Kolimaga JT, Zullig LL, Weeks JC, Ayanian JZ, Kahn KL, Ganz PA, Catalano PJ, West DW and Provenzale D. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer 2012; 119: 854-862.
4. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL and Hoon DS. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150: 2143-2152.
5. Prins RM, Odesa SK and Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63: 8487-8491.
6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
7. Lucas S, De Plaen E and Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 2000; 87: 55-60.
8. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H and Akiyoshi T. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995; 109: 1522-1525.
9. Wischnewski F, Pantel K and Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006; 4: 339-349.
10. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T and van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 1999; 29: 3329-3337.
11. Rosenberg SA, Yang JC and Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
12. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB and Lyerly HK. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3: 9.
13. Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M and Velu T. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 2001; 69: 937-943.
14. Park MS, Park JW, Jeon CH, Lee KD and Chang HK. Expression of melanoma antigen-encoding genes (MAGE) by common primers for MAGE-A1 to -A6 in colorectal carcinomas among Koreans. J Korean Med Sci 2002; 17: 497-501.
15. Gerhardt A, Usener D, Keese M, Sturm J, Schadendorf D and Eichmuller S. Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett 2004; 208: 197-206.
16. Koketsu S, Watanabe T, Kazama S, Ishihara S, Komuro Y and Nagawa H. What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology 2004; 51: 1648-1652.
17. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y and Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005; 11: 1809-1814.
18. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, Mc Mahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM and Rosenberg SA. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36: 133-151.
19. Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K, Kim SU and Ikenaka K. MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 2001; 61: 4809-4814.
20. Kramer BF, Schoor O, Kruger T, Reichle C, Muller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee HG and Stevanovic S. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther 2005; 4: 943-948.
21. Ito S, Kawano Y, Katakura H, Takenaka K, Adachi M, Sasaki M, Shimizu K, Ikenaka K, Wada H and Tanaka F. Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung Cancer 2006; 51: 79-88.
22. Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, Prime SS, Teo SH, Silvio Gutkind J, Patel V and Cheong SC. Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett 2012; 321: 18-26.
23. Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, Mc Donnell S, Hughes L, Crown J and O'Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer 2012; 130: 1991-2002.
24. Oya H, Kanda M, Takami H, Hibino S, Shimizu D, Niwa Y, Koike M, Nomoto S, Yamada S, Nishikawa Y, Asai M, Fujii T, Nakayama G, Sugimoto H, Fujiwara M and Kodera Y. Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus 2013; [Epub ahead of print].
25. Takami H, Kanda M, Oya H, Hibino S, Sugimoto H, Suenaga M, Yamada S, Nishikawa Y, Asai M, Fujii T, Nomoto S and Kodera Y. Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol 2013; 108: 557-562.
26. Chung FY, Cheng TL, Chang HJ, Chiu HH, Huang MY, Chang MS, Chen CC, Yang MJ, Wang JY and Lin SR. Differential gene expression profile of MAGE family in taiwanese patients with colorectal cancer. J Surg Oncol 2010; 102: 148-153.
27. LH S, MK G and C W. TNM Classification of Malignant Tumors. 7th edition. Oxford: Wiley-Blackwell 2009. pp. 100-105.
28. Luo B, Yun X, Fan R, Lin YD, He SJ, Zhang QM, Mo FR, Chen F, Xiao SW and Xie XX. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol 2013; 6: 2835-2845.
29. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA and Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004; 10: 5145-5150.
30. He SJ, Gu YY, Yu L, Luo B, Fan R, Lin WZ, Lan XW, Lin YD, Zhang QM, Xiao SW and Xie XX. High expression and frequently humoral immune response of melanoma- associated antigen D4 in glioma. Int J Clin Exp Pathol 2014; 7: 2350-2360.
31. Zhou SF, Mo FR, Bin YH, Hou GQ, Xie XX and Luo GR. Serum immunoreactivity of SMP30 and its tissues expression in hepatocellular carcinoma. Clin Biochem 2010; 44: 331-336.
32. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L and Samaha RR. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006; 7: 59.
33. Jeon CH, Kim DD, Lee HI, Oh HK and Chae HD. Melanoma-associated antigen (MAGE) expression in the normal mucosa around colorectal cancer after curative resection: presence of undetectable free cancer cells. Int J Biol Markers 2011; 26: 88-93.
34. Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000; 11: 176-184.
35. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, Chen YT and Jungbluth AA. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
36. Meek DW and Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012; 324: 126-132.
37. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J and Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994; 54: 1766-1771.
38. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M and Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004; 64: 9167-9171.
39. Zhang QM, Shen N, He SJ, Xie S, Bi SQ, Luo B, Lin YD, Fu J, Zhou SF, Xiao SW and Xie XX. MAGED4 Expression in Glioma and Upregulation in Glioma Cell Lines with 5-Aza-2/-deoxytidine Treatment. Asian Pac J Cancer Prev 2014; 15: 3495-3501.
40. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363-3367.
41. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y and Toda M. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 2004; 23: 1420-1427.
42. Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, Qian F, Schneider S, Sharma S, Driscoll D, Lele S, Old LJ, Nakayama E and Odunsi K. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 2006; 29: 903-910.
43. Tureci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, Sester U, Sybrecht GW and Sahin U. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006; 236: 64-71.
44. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A and Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 4041-4047.
45. Lu H, Goodell V and Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388-1394.
46. Caballero OL and Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.